 Home > Active Ingredient News > Antitumor Therapy > Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange, bravely breaking into the 100 billion cell therapy market!

Keji Pharmaceutical was officially listed on the Hong Kong Stock Exchange, bravely breaking into the 100 billion cell therapy market!

 Last Update: 2021-06-28
 Source: Internet
 Author: User

Tags

alk cancer

phillips 66 company

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

2021 Nian 6 Yue 18 days, Cozi Pharmaceutical officially listed on the Hong Kong Stock Exchange, has become a Chinese cell therapy companies in the secondary market
.

The IPO attracted support from global technology hedge funds Cloud Alpha , Dymon Asia Fund and other institutions

2021 Nian 6 Yue 18 days, Cozi Pharmaceutical officially listed on the Hong Kong Stock Exchange, has become a Chinese cell therapy companies in the secondary market

The predecessor was Keji Bio.
After the reorganization and consolidation before listing, Keji Bio was a subsidiary of Keji Pharmaceutical .

Founded in 2014 , Keji Pharmaceutical is a biopharmaceutical company with operations in China and the United States, focusing on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors .
The predecessor was Keji Bio.
After the reorganization and consolidation before the listing, Keji Bio was a subsidiary of Keji Pharmaceutical .

CAR-T is subjected to a genetically modified T cells to the patient through DNA introduced into encoding CAR gene of T modified cells, T proliferated cells expressing the patient reinfusion CAR , to initiate the body's natural defense mechanisms of the host, target The cells are killed, so as to achieve a stronger ability to locate and attack tumor cells than ordinary T cells

In recent years, CAR-T cell therapy has become a global research and development hotspot, and the number of clinical trials has exploded

Although Keji Pharmaceutical has not yet commercialized its products, its rich product line is quite interesting.

Image source: Keji Pharmaceutical

Keji Pharmaceutical's core CAR-T drug CT053 is currently in Phase 2 of
the clinical phase, and the progress is in the first echelon in China, and it is also one of the most mature products .

CT053 is mainly used for the treatment of relapsed and refractory multiple myeloma.

Keji Pharmaceutical's core CAR-T drug CT053 is currently in Phase 2 of

The main clinical data of CT053 comes from the Chinese IIT trial.
After a 6 -month follow-up of 24 patients, it was found that CT053 achieved an objective response rate of 87.
5% and a complete response of 79.
2% , and the median duration of sustained response reached 21.

In fact, in March this year, the US FDA has approved the BCMA CAR-T cell therapy product Abecma to be marketed for the treatment of adult patients with relapsed / refractory multiple myeloma

However, in terms of safety, in terms of safety, all patients receiving Abecma treatment have a good safety status, mainly low-level cytokine release syndrome ( CRS ) and neurotoxicity ( NT ), and have a Predicted early onset and remission

CT053 shows a clear competitive advantage in terms of safety

At the same time, it is worth mentioning that, by the same economic medicine department independent research and development CT041 get the world's only targeting CLDN18.
2 of CART-T product candidates
.
CT041 is a humanized anti Claudin18.
2 ( CLDN18.
2 ) autologous CAR-T therapy for the treatment of CLDN18.
2 positive expression progress past or through the system after treatment in patients with advanced gastric adenocarcinoma / esophagogastric junction gland Cancer, pancreatic cancer
.
CT041 is a humanized anti Claudin18.
2 ( CLDN18.
2 ) autologous CAR-T therapy for the treatment of CLDN18.
2 positive expression progress past or through the system after treatment in patients with advanced gastric adenocarcinoma / esophagogastric junction gland Cancer, pancreatic cancer
.

Studies have shown that CLDN18.
2 is highly expressed in gastric cancer, pancreatic cancer, colon cancer, lung cancer, esophageal cancer, ovarian cancer and other tumors
.
Approximately 50% to 80% of patients
in gastric cancer have the expression of this target .
In 2019 , Keji Pharmaceuticals published the results of CAR-T cell research targeting CLDN18.
2 for the first time in the world , and found that CAR-T cells targeted by CLDN18.
2 can efficiently eliminate gastric adenocarcinoma in mice with good safety.
Therefore, it is expected to become a new treatment method for gastric adenocarcinoma and other tumors .
In addition, CT011 is the world's first targeted GPC3 candidate product to enter clinical trials .

Currently, there are as yet commercialized product, Cozi medicine is still at a loss stage, not yet generated any revenue from product sales, the fastest commercialization of CT053 is expected in China or the US commercial time is 2022 Nian and 2023 Nian
.

Compared with traditional small molecule drugs and antibody drugs, the layout of CAR-T technology is more complicated, involving multiple links such as basic research, industrial preparation, and clinical use
.
Since CAR-T therapy is cultivated according to the patient's own cells, the treatment cost is often as high as hundreds of thousands or even millions.
Whether it can be popularized in the future depends on the cost reduction and the intervention of medical insurance
.
Compared with traditional small molecule drugs and antibody drugs, the layout of CAR-T technology is more complicated, involving multiple links such as basic research, industrial preparation, and clinical use
.
Sincecompared to the conventional antibody drugs and small molecule drugs, layout CAR-T technology is more complex, involving multiple aspects of basic research, industrial preparation, and the like for clinical use
.
Therapies are cultivated based on the patient's own cells.
Therefore, the cost of treatment is often hundreds of thousands or even millions.
Whether it can be popularized in the future depends on the reduction of costs and the intervention of medical insurance
.
In terms of cost reduction, it is also an important consideration for Keji Pharmaceutical
.
Dr.
Li Zonghai said with emotion that the cost of CAR-T treatment is currently high.
After the drug is launched, we are most worried that the common people cannot afford it
.
We hope to reduce costs in various ways and benefit more people
.
In terms of cost reduction, it is also an important consideration for Keji Pharmaceutical
.
Dr.
Li Zonghai said with emotion that the cost of CAR-T treatment is currently high.
After the drug is launched, we are most worried that the common people cannot afford it
.
We hope to reduce costs in various ways and benefit more people
.
At present, the cost of CAR-T treatment is high.
After the drug is on the market, we are most worried that the common people cannot afford it
.
We hope to reduce costs in various ways and benefit more people
.

It is reported that the current economic medicine department in order to reduce the cost of treatment, Cozi medicine from the industrial preparation to minimize the production processes and improve efficiency
.
Cozi medicine has been established in line with GMP covers plasmid production, lentiviral vector production and CAR-T cells in the production of end-to-house manufacturing capacity
.
In Xuhui District, Shanghai, it has established a production plant with a total construction area of approximately 3,000 square meters.
The annual production capacity of CAR-T in this plant supports the use of CAR-T to treat 200 patients
.
And located in Jinshan District of Shanghai completed the construction of commercial-scale production plant, the plant is expected to be supported each year using CAR-T treatment as many as 2,000 patients, and to CAR-T treatment won China's first CAR-T cell therapy In addition, Keji Pharmaceuticals is also planning to build a phase II production plant in Jinshan and build a GMP- compliant production plant in the United States to support the treatment of more than 10,000 patients each year .

It is reported that the current economic medicine department in order to reduce the cost of treatment, reported that the current economic medicine department in order to reduce the cost of treatment, Cozi medicine from the industrial preparation to minimize the production processes and improve efficiency
.
Keji Pharmaceutical Co.
, Ltd.
has minimized production links from industrial preparation and improved efficiency
.
Industrial production has established end-to-end internal manufacturing capabilities that comply with GMP covering plasmid production, lentiviral vector production and CAR-T cell production
.
In Xuhui District, Shanghai, it has established a production plant with a total construction area of approximately 3,000 square meters.
The annual production capacity of CAR-T in this plant supports the use of CAR-T to treat 200 patients
.
And located in Jinshan District of Shanghai completed the construction of commercial-scale production plant, the plant is expected to be supported each year using CAR-T treatment as many as 2,000 patients, and to CAR-T treatment won China's first CAR-T cell therapy In addition, Keji Pharmaceuticals is also planning to build Phase II of the production plant in Jinshan and build in the United States.
The production plant required by GMP to support the treatment of more than 10,000 patients per year .

According to Frost & Sullivan analysis, estimated that the global CAR-T sales value of cell therapy market up to 2024 years of 66 billion dollars, 2019 Nian to 2024 year compound annual growth rate of 55%
.
By 2030 , in terms of sales value, the global CAR-T market is expected to reach 21.
8 billion U.
S.
dollars, with a compound annual growth rate of 22.
1% from 2024 to 2030 .

We expect the global CAR-T sales value of cell therapy market up to 2024 years of 66 billion dollars, 2019 Nian to 2024 year compound annual growth rate of 55%
.
By 2030 , in terms of sales value, the global CAR-T market is expected to reach 21.
8 billion U.
S.
dollars.
From 2024 to 2030The annual compound annual growth rate is 22.
1%
.

With the rapid expansion
of the CAR-T cell therapy market, CAR-T patents have shown rapid growth in the past decade .
According to data from the United States Patent and Trademark Office (USPTO) , the average development speed of CAR-T patents in the past ten years was 2.
09 , while the baseline level of the patent population was 1.
05
.
However, in this fast-growing field, a comprehensive patent analysis has not yet been conducted
.

With the rapid expansion
of the CAR-T cell therapy market, CAR-T patents have shown rapid growth in the past decade .
The cell therapy market has expanded rapidly, and CAR-T patents have shown rapid growth in the past decade
.
According to the US Patent and Trademark Office (USPTO) data, CAR-T patents in the last decade CAR-T patents in the last decade the average growth rate was 2.
09 , while the patented baseline population was 1.
05
.
However, in this fast-growing field, a comprehensive patent analysis has not yet been conducted
.

To this end, through patent scanning, the team of Professor Hu Yuanjia from the University of Macau comprehensively analyzed CAR-T 's global patent layout from the four dimensions of " time - space - organization - technology " , and provided an " aerial image " of patented technology in this field for the first time .
The results were published in the latest Nature biotechnology journal .

The application trend of CAR-T patent

The results show that the first 20 Ming CAR-T inventors are located in the United States, Britain and France
.
Among them, one of the creators of CAR-T , Carl H.
June of the United States is the one who has obtained the most patents; followed by Martin Pule and Shaun Cordoba from the United Kingdom
.
In terms of company patent rights, the University of Pennsylvania, the pharmaceutical company Bristol-Myers Squibb, and Novartis of Switzerland ranked in the top three respectively
.
The only squeeze in before 20 strong patent ownership of Chinese companies Cozi medicine, No.
18 Wei
.

The results show that the first 20 Ming CAR-T inventors are located in the United States, Britain and France
.
Among them, one of the creators of CAR-T , Carl H.
June of the United States is the one who has obtained the most patents; followed by Martin Pule and Shaun Cordoba from the United Kingdom
.
In terms of company patent rights, the University of Pennsylvania, the pharmaceutical company Bristol-Myers Squibb, and Novartis of Switzerland ranked in the top three respectively
.
The only squeeze in before the only former squeeze in 20 strong patent ownership of Chinese companies Cozi medicine, No.
18 Wei
.
20 strong patent rights for the Chinese company has Cozi medicine, No.
18 Wei
.

The study emphasizes that the development of CAR-T research in China is not early, but the speed is very rapid
.
At present, China has become the world's first patent disclosure country and the world's second patent ownership country
.
However, we can still find that there is still a big gap between us and the powerful countries in Europe and America - although there are a large number of patent rights institutions, their small scale, lack of cooperation and international layout have resulted in a marginal position in the global R&D network
.

The study emphasizes that the development of China's CAR-T research in China is not early, but the speed is very rapid
.
At present, China has become the world's first patent disclosure country and the world's second patent ownership country
.
However, we can still find that there is still a big gap between us and the powerful countries in Europe and America.
The development of research is not early, but the speed is very rapid
.
At present, China has become the world's first patent disclosure country and the world's second patent ownership country
.
- patent agency although the quantity, but the small size, lack of cooperation and international distribution, leading edge position in the global R & D network
.

CAR-T treatment TOP20 target

From a global perspective, CAR-T is currently focused on the therapeutic targets CD19 , BCMA , -CD20 , of Mesothelin , the PD-.
1 / the PD-Ll , and HER-2 and the like
.
At the same time, China's patent system also has a great impact on other countries' entry into China
.
China is considering whether innovative developers can obtain patent approval in China before entering the market to deter potential competitors
.
The economic benefits brought by the excellent clinical efficacy of CAR-T technology and the market demand brought by China's huge population base have aroused great enthusiasm and interest from researchers and companies all over the world
.
From a global perspective, CAR-T is currently focused on the therapeutic targets CD19 , BCMA , -CD20 , of Mesothelin , the PD-.
1 / the PD-Ll , and HER-2 and the like
.
At the same time, China's patent system also has a great impact on other countries' entry into China
.
China is considering whether innovative developers can obtain patent approval in China before entering the market to deter potential competitors
.
CAR-TThe economic benefits brought about by technologically superior clinical efficacy and the market demand brought about by China's huge population base have aroused great enthusiasm and interest from researchers and companies all over the world
.

With the official listing of Keji Pharmaceutical on the Hong Kong Stock Exchange, we look forward to the launch of China's first CAR-T cell therapy drug, and we look forward to the strength of China's local forces to overtake in corners and let the world know that China is not lagging behind
.
In any case, cellular immunotherapy is about to usher in its own golden decade!

With the launch of CAR-T cell therapy drugs, it is hoped that Chinese local forces will have the strength to overtake in corners and let the world know that China is not lagging behind
.
In any case, cellular immunotherapy is about to usher in its own golden decade! Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.